{"id":12,"date":"2026-08-17T12:53:22","date_gmt":"2026-08-17T12:53:22","guid":{"rendered":"https:\/\/peptide-doc.com\/learn\/tirzepatide\/"},"modified":"2026-09-02T19:41:50","modified_gmt":"2026-09-02T19:41:50","slug":"tirzepatide","status":"publish","type":"learn_article","link":"https:\/\/peptide-doc.com\/de\/learn\/tirzepatide\/","title":{"rendered":"Tirzepatide"},"content":{"rendered":"
\nMETA-TITLE:<\/strong> [TODO: Tirzepatide \u2014 Dual Agonist Research Profile | Brand]
\nMETA-DESC:<\/strong> [TODO: Comprehensive tirzepatide profile covering dual GLP-1\/GIP agonism, SURMOUNT trial data, research dosing, safety.]\n<\/div>\n

[TODO]<\/span> Hook \u2014 tirzepatide (Mounjaro\/Zepbound) as first-in-class GLP-1\/GIP dual agonist, FDA approvals, research significance<\/p>\n

[IMAGE: Tirzepatide molecular structure or branded vial photograph]<\/div>\n

What is Tirzepatide?<\/h2>\n
    \n
  • [TODO]<\/span> Full name \u2014 Tirzepatide (LY3298176), brand names Mounjaro \/ Zepbound<\/li>\n
  • [TODO]<\/span> Developer \u2014 Eli Lilly<\/li>\n
  • [TODO]<\/span> Classification \u2014 GLP-1\/GIP dual receptor agonist, 39-amino acid peptide<\/li>\n
  • [TODO]<\/span> FDA status \u2014 approved for T2D (2022), obesity (2023)<\/li>\n
  • [TODO]<\/span> Key distinction \u2014 first molecule to agonize both incretin receptors simultaneously<\/li>\n<\/ul>\n

    Mechanism of Action<\/h2>\n
    [IMAGE: Dual receptor pathway diagram \u2014 GLP-1R and GIPR activation, downstream metabolic effects]<\/div>\n
      \n
    • [TODO]<\/span> GLP-1R activation \u2014 appetite reduction, delayed gastric emptying, insulin secretion<\/li>\n
    • [TODO]<\/span> GIPR activation \u2014 enhanced insulin sensitivity, adipose tissue signaling, unclear weight mechanism<\/li>\n
    • [TODO]<\/span> C20 fatty acid moiety \u2014 albumin binding, half-life ~5 days<\/li>\n
    • [TODO]<\/span> Biased agonism \u2014 different signaling profile vs native GLP-1\/GIP<\/li>\n<\/ul>\n

      Research Highlights<\/h2>\n
        \n
      • [TODO]<\/span> SURMOUNT-1 \u2014 up to 22.5% body weight reduction (15mg, 72 weeks)<\/li>\n
      • [TODO]<\/span> SURMOUNT-2 \u2014 T2D population, 14.7% weight reduction<\/li>\n
      • [TODO]<\/span> SURPASS trials \u2014 HbA1c reduction, superior to semaglutide in SURPASS-2<\/li>\n
      • [TODO]<\/span> Cardiovascular \u2014 SURPASS-CVOT pending, interim data positive<\/li>\n
      • [TODO]<\/span> Body composition \u2014 greater fat mass reduction vs lean mass<\/li>\n<\/ul>\n

        Dosing Protocols (Research Context)<\/h2>\n
          \n
        • [TODO]<\/span> Starting dose \u2014 2.5mg weekly for 4 weeks<\/li>\n
        • [TODO]<\/span> Titration \u2014 2.5mg increments every 4 weeks<\/li>\n
        • [TODO]<\/span> Maintenance \u2014 5mg, 10mg, or 15mg weekly<\/li>\n
        • [TODO]<\/span> Administration \u2014 subcutaneous, once weekly, rotate injection sites<\/li>\n<\/ul>\n

          Safety & Considerations<\/h2>\n
            \n
          • [TODO]<\/span> GI effects \u2014 nausea (most common), diarrhea, constipation; typically diminish with titration<\/li>\n
          • [TODO]<\/span> Pancreatitis \u2014 rare but monitored; contraindicated with history<\/li>\n
          • [TODO]<\/span> Gallbladder \u2014 increased cholelithiasis incidence with rapid weight loss<\/li>\n
          • [TODO]<\/span> Injection site reactions \u2014 mild, transient<\/li>\n<\/ul>\n

            Frequently Asked Questions<\/h2>\n
            [FAQ: How does tirzepatide compare to semaglutide in weight reduction?]<\/div>\n
            [FAQ: Why does tirzepatide target two receptors instead of one?]<\/div>\n
            [FAQ: What is the recommended titration schedule?]<\/div>\n
            [FAQ: Can tirzepatide be stored at room temperature?]<\/div>\n

            Related Products<\/h2>\n

            [TODO]<\/span> Link to Tirzepatide product page + Weight Management category<\/p>\n","protected":false},"excerpt":{"rendered":"

            [META-DESC TODO: Tirzepatide research profile \u2014 GLP-1\/GIP dual agonist, SURMOUNT trials, mechanism, dosing protocols.]<\/p>\n","protected":false},"featured_media":0,"template":"","learn_category":[2],"class_list":["post-12","learn_article","type-learn_article","status-publish","hentry","learn_category-weight-management"],"_links":{"self":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article\/12","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article"}],"about":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/types\/learn_article"}],"version-history":[{"count":1,"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article\/12\/revisions"}],"predecessor-version":[{"id":35,"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_article\/12\/revisions\/35"}],"wp:attachment":[{"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/media?parent=12"}],"wp:term":[{"taxonomy":"learn_category","embeddable":true,"href":"https:\/\/peptide-doc.com\/de\/wp-json\/wp\/v2\/learn_category?post=12"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}